FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.
What happened
FDA inspected United Health Products from September 23 to October 4, 2024, as sponsor of a clinical study of CelluSTAT Absorbable Hemostat. FDA found the company began the significant-risk study without submitting an IDE application or getting FDA approval, and that it gave the IRB modified FDA correspondence implying FDA agreed the study was non-significant risk. FDA also found inadequate monitoring, enrollment of subjects who met an exclusion criterion, unsigned consent forms, unevaluated adverse device effects, and inaccurate device accountability records.
What FDA found
The company began a significant-risk clinical study without submitting an Investigational Device Exemption (IDE) application to FDA or getting FDA approval first, and it gave the IRB altered FDA correspondence that misrepresented the study as non-significant risk.
21 CFR 812.20(a)(1) and (2)The company did not have an effective monitoring plan during the study and lacked adequate site initiation and interim monitoring records.
21 CFR 812.40The company did not ensure investigators followed the study plan: 40 subjects met an exclusion criterion and three subjects' consent forms were unsigned, and it did not stop device shipments or terminate the investigator.
21 CFR 812.46(a)The company did not document evaluation of two unanticipated adverse device effects for subject 02-0074 and did not report evaluation results to FDA and IRBs within 10 working days.
21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)Device accountability records were inaccurate: the master log counted 230 and 4 device recipients at two sites, while only 118 subjects were randomized and site inventory showed different use.
21 CFR 812.140(b)(2)
What FDA wants
Within 15 working days, provide documentation of additional corrective and preventive actions, projected completion dates, and a plan to monitor effectiveness. Reference the cited CTS# and email the response to Irfan.Khan@fda.hhs.gov, with a copy to OII BIMO Division 1.
Who should pay attention
- sponsors of device clinical trials
- IRBs reviewing significant-risk device studies
- developers of absorbable implantable hemostats
This is a summary. Read the original letter on fda.gov.